Clinical trials: Complication of Dialysis
Chronic Kidney Disease, Chronic Renal Disease
Study of How the Dose of Dialysis is Affected by Dialysate Flow Rate
The purpose of this study is to look at how the dose of dialysis is affected by the rate at which dialysate flows through the dialyzer.
- Trial name
- NCT00962000
- Testing
- Dialysis Flow Rate Start 600mL/min, Dialysis Flow Rate Start 800mL/min
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Vantive Health LLC
Hyperkalemia, Chronic Kidney Disease
Prediction of Hyperkalemia in Dialysis Patients Through Waveform Analysis Using Wearable ECG
This study aims to evaluate whether hyperkalemia, a potentially life-threatening condition in dialysis patients, can be detected early using a wearable single-lead ECG device.
- Trial name
- NCT07054905
- Testing
- HiCardi wearable ECG
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Kyungho Park
Inflammation on Dialysis, Bacteriuria in Hemodialysis Patients
Clinical Impact of Bacteriuria on Chronic Inflammation in Asymptomatic Hemodialysis Patients
When considering occult infections during the diagnostic workup of inflammation in Hemodialysis (HD) patients, the urine-deprived bladder is frequently dismissed as potential site of infection.
- Trial name
- NCT01570556
- Testing
- Antibiotic treatment
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Assaf-Harofeh Medical Center
Renal Insufficiency
Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function
The purpose of this study is to evaluate tirofiban concentration in the blood over a period of 24 hours after tirofiban administration. Subjects with varying degrees of renal insufficiency (i.e.
- Trial name
- NCT01766154
- Testing
- Tirofiban
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Medicure
Chronic Kidney Disease
Behavioral AI to Predict and Increase Peritoneal Dialysis Uptake
Scaled Insights Behavioral AI will be used to improve clinicians ability to detect and understand: The likelihood of patients with kidney failure opting for peritoneal dialysis and to select the right personalized nudge to get…
- Trial name
- AI (NCT06533254)
- Testing
- Predicting choice of dialysis, Behavioral nudges
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Scaled Insights
Chronic Kidney Diseases
Safety of and Tolerability to a Sodium-free Peritoneal Dialysis Solution
This study will evaluate the safety and tolerability profile of a dwell time (bath) of 24 hours using a 500 ml sodium-free peritoneal dialysis solution based on 30% icodextrin and 10% dextrose in patients with chronic kidney…
- Trial name
- NCT05780086
- Testing
- 30% icodextrin and 10% dextrose
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Instituto Mexicano del Seguro Social
Kidney Diseases, Dialysis; Complications
PRevEnting FracturEs in REnal Disease - 1
PREFERRED-1 is a pilot study designed to determine the feasibility of a large randomized, pragmatic, open-label, comparative-effectiveness trial of denosumab for the prevention of fragility fractures in people receiving…
- Conditions
- Kidney Diseases, Dialysis; Complications, Fragility Fracture, Chronic Kidney Disease-Mineral and Bone Disorder
- Trial name
- PREFERRED-1 (NCT05096195)
- Testing
- Denosumab 60 mg/ml, Calcium and vitamin D prophylaxis, Monitoring of post-injection calcium and phosphate
- Where
- 6 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Western University, Canada
End Stage Renal Disease
Mid-HDF Randomized Controlled Study on Outcome
The purpose of this study is to determine whether mid-dilution hemodiafiltration is effective in the reduction of the crude mortality risk in patients who have been undergoing renal replacement treatment for less than 1 year.
- Trial name
- MILESTONE (NCT01693354)
- Testing
- Mid-dilution HDF, HF dialysis
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 500 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Fluid Overload, Peritoneal Hyperpermeability
Hydratation Status at Initiation of Peritoneal Dialysis: Study of the Role of Peritoneal Permeability
Bioimpedance is recently known to be a reliable, reproducible and validated technic allowing determination of hydratation status in patients with chronic kidney disease treated with peritoneal dialysis (PD).
- Conditions
- Fluid Overload, Peritoneal Hyperpermeability, Peritoneal Dialysis, Chronic Kidney Disease
- Trial name
- NCT03322410
- Testing
- modified Peritoneal Equilibration test
- Where
- France
- Volunteers
- 40 people
- Sponsor
- CHU de Reims
ESRD
Interactive Videoconferencing in the Provision of Remote Peritoneal Dialysis
Home dialysis patients must be seen in a face to face visit on a monthly basis. For patients who live remotely these visits may impact their quality of life due to the amount of time needed to attend these visits.
- Trial name
- Telemedicine (NCT02428803)
- Testing
- Telemedicine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Alabama at Birmingham
ESRD (End Stage Renal Disease)
Fluid Status of Dialysis Subjects
The goal of this clinical pilot study is to evaluate the ability of the device to properly detect the hydration status of the subject through the study of fluid removal data during dialysis and HemoCept device data.
- Trial name
- NCT07217041
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- HemoCept Inc.
End Stage Renal Disease
A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis
The purpose of this study is to determine if AAT-023 (Zuragen) solution is superior to Heparin in preventing Catheter Related Blood Stream Infections for End Stage Renal Disease patients.
- Trial name
- NCT00628680
- Testing
- AAT-023 solution (Zuragen), Heparin
- Where
- 22 sites in United States
- Volunteers
- 415 people
- Sponsor
- Ash Access Technology
Renal Insufficiency
Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects
The aim of the study is to assess whether renal impairment could affect fevipiprant pharmacokinetics (PK) to the extent that dosage adjustment is appropriate for this patient population.
- Trial name
- NCT03087942
- Testing
- QAW039, QAW39A, QAW39A2107
- Where
- 2 sites in United States, Germany
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Kidney Disease
Neck-Worn Monitoring Sensor for - A Study for Monitoring Subjects With Fluid-Management Issues During Dialysis
The study has two objectives based on the intended-use measurements and populations described above. The first objective is to show that relative changes in impedance as measured by the test device (ΔSFI) are strongly correlated…
- Trial name
- NCT02140905
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Baxter Healthcare Corporation
End Stage Renal Disease
Fluid Restriction and Quality of Life on Dialysis
Almost 30,000 people in the UK receive dialysis due to end stage renal disease (ESRD). Although dialysis prolongs life, people receiving dialysis are still typically bothered by a range of physical symptoms and need to make…
- Trial name
- NCT05264220
- Testing
- ACT Matrix
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- University of Oxford
Chronic Kidney Diseases, Pruritus
CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of oral difelikefalin administered as a 1 mg tablet once daily compared to placebo in reducing the intensity of itch in…
- Trial name
- NCT05356403
- Testing
- Difelikefalin 1 mg Oral Tablet
- Where
- 75 sites in United States, Argentina and 11 more
- Volunteers
- 105 people
- Sponsor
- Cara Therapeutics, Inc.
Chronic Kidney Diseases, Colon Polyp
Low-volume vs High-volume Polyethylene Glycol Based Bowel Preparation for Colonoscopy in People Receiving Hemodialysis
Current American Society for Gastrointestinal Endoscopy (ASGE) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines recommend a split regimen of high-volume (4-liter polyethylene glycol-based preparation) or…
- Conditions
- Chronic Kidney Diseases, Colon Polyp, Dialysis; Complications, Colon Cancer
- Trial name
- PrepDial (NCT04709770)
- Testing
- 2-liters polyethylene glycol with citrate and simethicone, 4-liters polyethylene glycol with simethicone, Low-residue diet
- Volunteers
- 264 people
- Sponsor
- Alfredo Di Leo
Arrythmia, Dialysis; Complications
Continuous 7-day Detection of Arrhythmias in Dialysis Population
The Carnation Ambulatory Monitor (CAM) is an innovative diagnostic patch device that allows to differentiate the different kinds of arrhythmias more precisely than any other ECG-monitoring device.
- Trial name
- NCT04071054
- Testing
- Carnation Ambulatory Monitor (CAM)
- Where
- Austria
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Peritoneal Dialysis Complication, Residual Kidney Function
Incremental PD With Single Icodextrin Exchange
Objectives: To investigate the efficacy and safety of single daily icodextrin exchange for initiation of incremental peritoneal dialysis (PD). Subjects: Seventy-two incident PD patients.
- Conditions
- Peritoneal Dialysis Complication, Residual Kidney Function, Survival, Health-related Quality of Life
- Trial name
- NCT06119373
- Testing
- Single daily icodextrin exchange, Conventional PD group
- Volunteers
- 72 people
- Sponsor
- RenJi Hospital
Anemia, End Stage Renal Disease (ESRD)
Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
This study was conducted to explore a new therapy for anemia in participants with end stage renal disease (ESRD) on dialysis. Anemia is a reduced number of red blood cells or hemoglobin.
- Trial name
- Pyrenees (NCT02278341)
- Testing
- Roxadustat, Epoetin alfa, Darbepoetin alfa
- Where
- 143 sites in Belgium, Bulgaria and 15 more
- Volunteers
- 838 people
- Sponsor
- Astellas Pharma Europe B.V.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.